You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Na+/Ca2+ exhanger (NCX) inhibitor (IC50 ~ 100 nM); TRPP3 channel blocker (IC50 = 1.1 μM for inhibition of Ca2+-activated TRPP3 channel activity). Also non-selective Deg/ENaC family blocker; reduces mechanosensitivity of colonic afferents. More potent derivative of amiloride (Cat. No. 0890).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 356.21. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.81 mL||14.04 mL||28.07 mL|
|5 mM||0.56 mL||2.81 mL||5.61 mL|
|10 mM||0.28 mL||1.4 mL||2.81 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
References are publications that support the biological activity of the product.
Dai et al (2007) Inhibition of TRPP3 channel by amil. and analogs. Mol.Pharmacol. 72 1576 PMID: 17804601
Fischer et al (2002) Characterization of a Na+-Ca2+ exchanger in podocytes. Nephrol.Dial.Transplant. 17 1742 PMID: 12270979
Page et al (2007) Acid sensing ion channels 2 and 3 are required for inhibition of visceral nociceptors by benzamil. Pain 133 150 PMID: 17467171
If you know of a relevant reference for Benzamil, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Benzamil, Benzamil supplier, non-selective, Deg, ENaC, family, NCX, sodium, calcium, Na+/Ca2+, exchanger, inhibitors, inhibits, amiloride, derivative, TRPP3, channel, blocker, Exchanger, Epithelial, Sodium, Channels, TRPP, 3380, Tocris Bioscience
5 Citations for Benzamil
Citations are publications that use Tocris products. Selected citations for Benzamil include:
Panja et al (2019) Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity. Neuropathol Appl Neurobiol 45 141 PMID: 29679372
Mizuno et al (2019) Development of Orthogonal Linear Separation Analysis (OLSA) to Decompose Drug Effects into Basic Components. Sci Rep 9 1824 PMID: 30755704
Agarwal et al (2017) Transient Opening of the Mitochondrial Permeability Transition Pore Induces Microdomain Calcium Transients in Astrocyte Processes. Neuron 93 587 PMID: 28132831
Singh (2018) Determination of system level alterations in host transcriptome due to Zika virus (ZIKV) Infection in retinal pigment epithelium. Sci Rep 8 11209 PMID: 30046058
Zou et al (2018) Knockout of mitochondrial voltage-dependent anion channel type 3 increases reactive oxygen species (ROS) levels and alters renal sodium transport. J Biol Chem 293 1666 PMID: 29180450
Do you know of a great paper that uses Benzamil from Tocris? Please let us know.
Reviews for Benzamil
There are currently no reviews for this product. Be the first to review Benzamil and earn rewards!
Have you used Benzamil?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.